News for CSPC Pharmaceutical Group Limited (CHJTF)

BOSTON, Mass, April 01, 2025 (GLOBE NEWSWIRE) -- Radiance Biopharma, Inc. ('Radiance” or the 'Company”), a clinical stage biopharmaceutical company advancing Antibody Drug Conjugates ('ADCs'), today announced that the U.S. Food and Drug Administration ('FDA”) has cleared its Investigational New Drug ('IND”) application for RB-164™, an ROR-1 targeted ADC for hematologic and solid malignancies. The IND supports the initiation of a Phase 1 dose escalation and expansion clinical trial of RB-164™ in patients with ROR-1 positive hematologic and solid cancers in the United States of America.

BOSTON, Massachusetts, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Radiance Biopharma, Inc., ('Radiance' or the 'Company'), a biotechnology company, today announced that it has entered into an exclusive License agreement with CSPC Megalith Biopharmaceutical Co., Ltd, a subsidiary of CSPC Pharmaceutical Group Limited (CSPC; HKEX: 01093) for development and commercialization of RB-164 (SYS6005): a novel clinical stage antibody drug conjugate (ADC) targeting ROR-1. The agreement covers exclusive commercialization rights to RB-164 in the United States of America (USA), Canada, the European Union, the United Kingdom, Switzerland, Norway, Iceland, Liechtenstein, Albania, Montenegro, North Macedonia, Serbia, and Australia. CSPC will retain all rights to SYS6005 in the remaining global markets.

Elevation Oncology (ELEV) is gearing up to report EO-3021 phase 1 data to treat patients with advanced solid tumors. Read more for a detailed analysis of the stock.

Corbus Pharma is short of funds and has filed with the SEC to raise up to $300 million, which may cause dilution for investors. Read why CRBP stock is a hold.

Discover the key factors driving its growth, such as its use in the production of polyurethanes, surfactants, and more. Delve into the market's evolving...

Elevation Oncology Inc (ELEV) reported a net loss of $10.6 million for Q3 2023, compared to a net loss of $38.8 million for Q3 2022.The company's cash, cash eq

/PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies...

Vitamin C market is segmented based on source, application, process and product type. Based on source, the global market is segmented into natural and...

/PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies...

Penny stocks to watch before next week.

OTC Vitamins and Dietary Supplements Market By Form (Liquid, Powder, Tablet, Capsule) By Function (Immune Health, Digestive Health, Heart Health, Bone &...

/PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies...

Financial results for the first quarter ended with revenue of KRW 28.8 billion, up by 20 percent compared to the same period in 2022 HanAll made a strong start...

Increase in the number of people choosing active lifestyle and growing preference for caffeine beverages drive the growth of the global caffeine market. By...

Hong Kong shares traded in the green on Friday with the benchmark Hang Seng opening 3.36% higher. Investors and traders seem to have shrugged off a rise in COVID-19 cases in China which hit their highest since August.